Research-based pharmaceutical company BioInvent International has treated the first patient in a Phase II study of BI-505 in smoldering multiple myeloma.

Patients with asymptomatic myeloma (smoldering multiple myeloma) who have not developed symptoms of disease, where the condition can be detected only in laboratory tests, will participate in the study.

The current study involves up to 10 patients and evaluates disease activity following treatment with BI-505.

"The current study involves up to 10 patients and evaluates disease activity following treatment with BI-505."

Secondary objectives include safety, pharmacokinetics and assessment of biomarkers.

BioInvent CEO Cristina Glad said BI-505 marks BioInvent’s capability to initiate in-house clinical projects using the company’s FIRST technology and biological expertise.

"The first clinical study of BI-505 achieved our goals. The candidate drug was well tolerated and indicated therapeutic effect, since seven of a total of 29 patients with advanced multiple myeloma demonstrated stable disease for at least two months," Glad said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The start of this Phase II study is another important step forward for BI-505 and we believe that BI-505 has the potential to address a major unmet need in a broad population of patients."

Human antibody BI-505, which specifically binds to the ICAM-1 adhesion protein, was developed for the treatment of multiple myeloma.